[Bone loss induced by GnRH agonist treatment].
Onoe
Yoshiko
Y
Department of Obstetrics and Gynecology, Tokyo Women's Medical University.
Ohta
Hiroaki
H
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control; D004164:Diphosphonates / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D007987:Gonadotropin-Releasing Hormone; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide